Latest Resverlogix Corp. Stories

2015-03-16 16:25:41

RVX-208 the first selective bromodomain extra-terminal (BET) protein inhibitor being developed for patients with high residual risks of cardiovascular disease SAN DIEGO,

2015-03-04 08:32:05

Emerald Logic FACET software generates predictive models and identifies novel variables driving RVX-208 drug efficacy, safety and reduced MACE incidence TSX Exchange Symbol: RVX

2015-01-14 20:21:36

SAN FRANCISCO, CA, Jan. 14, 2015 /PRNewswire/ - Resverlogix Corp.

2014-11-03 16:27:22

CALGARY, Nov. 3, 2014 /PRNewswire/ - Resverlogix Corp. (TSX:RVX) today announced the appointment of Michael T. Sweeney, M.D., as senior vice president of clinical development. Dr.

2014-10-08 20:22:06

TSX Exchange Symbol: RVX CALGARY, Oct. 8, 2014 /CNW/ - Resverlogix Corp.

2014-10-01 16:26:30

TSX Exchange Symbol: RVX CALGARY, Oct. 1, 2014 /PRNewswire/ - Resverlogix Corp.

2014-09-02 08:30:49

Presented in 'State of the Art and Featured Research Session' at the 2014 European Society of Cardiology Congress TSX Exchange Symbol: RVX BARCELONA, Spain

2014-08-15 16:24:21

TSX Exchange Symbol: RVX CALGARY, Aug. 15, 2014 /PRNewswire/ - Resverlogix Corp.

2014-08-13 16:26:35

TSX Exchange Symbol: RVX CALGARY, Aug. 13, 2014 /PRNewswire/ - Resverlogix Corp.

2014-07-23 08:32:18

In addition, preliminary results from an Australian sponsored trial have yet to verify whether the mechanism of RVX-208 action may affect glucose metabolism.